The comparative effect of teriparatide and denosumab on activins, follistatins, and inhibins in women with postmenopausal osteoporosis
Authors' conclusion
In conclusion, activins B and AB, as well as the ratios of all activins to follistatin and of activin AB to FSTL3 increased with teriparatide treatment, possibly in a compensatory manner.
Study context
- Population
- Postmenopausal women with osteoporosis
- Participants
- 23 vs 22
- Comparison
- Teriparatide vs denosumab
- Teriparatiden = 23
- Denosumabn = 22
- Primary endpoint
- Circulating levels of the activins-follistatins-inhibins (AFI) system
- Follow-up
- 12 mo
Methodological detailsnon-randomized, open-label, head-to-head
- Non-randomized
- Open-label
- Head-to-head
Primary result
As reported in the abstract
Circulating AFI molecules
- Teriparatide increased activin B
- P=.01
- Teriparatide increased activin AB
- P=.004
- Teriparatide increased activin A/follistatin ratio
- P=.006
- Teriparatide increased activin B/follistatin ratio
- P=.007
- Teriparatide increased activin AB/follistatin ratio
- P<.001
- Teriparatide increased activin AB/FSTL3 ratio
- P=.034
Further findings
Group × time interactions (activins B, AB; activin AB/FSTL3), adjusted
- Significant P for trend robust after adjustment for BMI and LS BMD; lost for activin B after adjustment for previous antiresorptive treatment
Effect of teriparatide on BMD
- Attenuated when adjusted for baseline activin levels or their 12-mo changes
Original publication
The comparative effect of teriparatide and denosumab on activins, follistatins, and inhibins in women with postmenopausal osteoporosis. J Bone Miner Res. Published 8 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →